Literature DB >> 11286480

Postmenopausal endogenous oestrogens and risk of endometrial cancer: results of a prospective study.

A Zeleniuch-Jacquotte1, A Akhmedkhanov, I Kato, K L Koenig, R E Shore, M Y Kim, M Levitz, K R Mittal, U Raju, S Banerjee, P Toniolo.   

Abstract

We assessed the association of postmenopausal serum levels of oestrogens and sex hormone-binding globulin (SHBG) with endometrial cancer risk in a case-control study nested within the NYU Women's Health Study cohort. Among 7054 women postmenopausal at enrolment, 57 cases of endometrial cancer were diagnosed a median of 5.5 years after blood donation. Each case was compared to 4 controls matched on age, menopausal status at enrolment, and serum storage duration. Endometrial cancer risk increased with higher levels of oestradiol (odds ratio = 2.4 in highest vs lowest tertile, P for trend = 0.02), percent free oestradiol (OR = 3.5, P< 0.001), and oestrone (OR = 3.9, P< 0.001). Risk decreased with higher levels of percent SHBG-bound oestradiol (OR = 0.43, P = 0.03) and SHBG (OR = 0.39, P = 0.01). Trends remained in the same directions after adjusting for height and body mass index. A positive association of body mass index with risk was substantially reduced after adjusting for oestrone level. Our results indicate that risk of endometrial cancer increases with increasing postmenopausal oestrogen levels but do not provide strong support for a role of body mass index independent of its effect on oestrogen levels. Copyright 2001 Cancer Research Campaign http://www.bjcancer.com.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286480      PMCID: PMC2363831          DOI: 10.1054/bjoc.2001.1704

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  Risk of endometrial cancer following estrogen replacement with and without progestins.

Authors:  E Weiderpass; H O Adami; J A Baron; C Magnusson; R Bergström; A Lindgren; N Correia; I Persson
Journal:  J Natl Cancer Inst       Date:  1999-07-07       Impact factor: 13.506

Review 2.  Steroid hormones and endometrial cancer.

Authors:  P K Siiteri
Journal:  Cancer Res       Date:  1978-11       Impact factor: 12.701

3.  Proliferation kinetics of human endometrium during the normal menstrual cycle.

Authors:  A Ferenczy; G Bertrand; M M Gelfand
Journal:  Am J Obstet Gynecol       Date:  1979-04-15       Impact factor: 8.661

4.  Serum sex hormone-binding globulin capacity and the percentage of free estradiol in postmenopausal women with and without endometrial carcinoma. A new biochemical basis for the association between obesity and endometrial carcinoma.

Authors:  J A Nisker; G L Hammond; B J Davidson; A M Frumar; N K Takaki; H L Judd; P K Siiteri
Journal:  Am J Obstet Gynecol       Date:  1980-11-15       Impact factor: 8.661

5.  Serum 17 beta-estradiol and estrone levels in postmenopausal women with and without endometrial cancer.

Authors:  H L Judd; W E Lucas; S S Yen
Journal:  J Clin Endocrinol Metab       Date:  1976-08       Impact factor: 5.958

Review 6.  Theories of endometrial carcinogenesis: a multidisciplinary approach.

Authors:  M E Sherman
Journal:  Mod Pathol       Date:  2000-03       Impact factor: 7.842

7.  Free estradiol in postmenopausal women with and without endometrial cancer.

Authors:  B J Davidson; J C Gambone; L D Lagasse; T W Castaldo; G L Hammond; P K Siiteri; H L Judd
Journal:  J Clin Endocrinol Metab       Date:  1981-03       Impact factor: 5.958

8.  Plasma levels of fractionated estrogens and pituitary hormones in endometrial carcinoma.

Authors:  F Benjamin; S Deutsch
Journal:  Am J Obstet Gynecol       Date:  1976-11-15       Impact factor: 8.661

9.  Serum androgens and estrogens in postmenopausal women with and without endometrial cancer.

Authors:  H L Judd; B J Davidson; A M Frumar; I M Shamonki; L D Lagasse; S C Ballon
Journal:  Am J Obstet Gynecol       Date:  1980-04-01       Impact factor: 8.661

10.  Plasma estrogen in patients with endometrial hyperplasia and carcinoma.

Authors:  F A Aleem; M A Moukhtar; H C Hung; S L Romney
Journal:  Cancer       Date:  1976-11       Impact factor: 6.860

View more
  40 in total

1.  Two estrogen-related variants in CYP19A1 and endometrial cancer risk: a pooled analysis in the Epidemiology of Endometrial Cancer Consortium.

Authors:  Veronica Wendy Setiawan; Jennifer A Doherty; Xiao-Ou Shu; Mohammad R Akbari; Chu Chen; Immaculata De Vivo; Angela Demichele; Montserrat Garcia-Closas; Marc T Goodman; Christopher A Haiman; Susan E Hankinson; Brian E Henderson; Pamela L Horn-Ross; James V Lacey; Loic Le Marchand; Douglas A Levine; Xiaolin Liang; Jolanta Lissowska; Galina Lurie; Monica McGrath; Steven A Narod; Timothy R Rebbeck; Giske Ursin; Noel S Weiss; Yong-Bing Xiang; Hannah P Yang; Wei Zheng; Sara H Olson
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-01       Impact factor: 4.254

2.  Prospective study of body fat distribution and the risk of endometrial cancer.

Authors:  Woong Ju; Hyun Ja Kim; Susan E Hankinson; Immaculata De Vivo; Eunyoung Cho
Journal:  Cancer Epidemiol       Date:  2015-06-09       Impact factor: 2.984

Review 3.  Regulation of 17β-hydroxysteroid dehydrogenases in cancer: regulating steroid receptor at pre-receptor stage.

Authors:  Mirja Rotinen; Joaquín Villar; Ignacio Encío
Journal:  J Physiol Biochem       Date:  2012-02-29       Impact factor: 4.158

4.  Premenopausal Circulating Androgens and Risk of Endometrial Cancer: results of a Prospective Study.

Authors:  Tess V Clendenen; Kathryn Hertzmark; Karen L Koenig; Eva Lundin; Sabina Rinaldi; Theron Johnson; Vittorio Krogh; Göran Hallmans; Annika Idahl; Annekatrin Lukanova; Anne Zeleniuch-Jacquotte
Journal:  Horm Cancer       Date:  2016-02-29       Impact factor: 3.869

5.  Analysis of serum metabolic profiles in women with endometrial cancer and controls in a population-based case-control study.

Authors:  Mia M Gaudet; Roni T Falk; Robert D Stevens; Marc J Gunter; James R Bain; Ruth M Pfeiffer; Nancy Potischman; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Montserrat Garcia-Closas; Christopher B Newgard; Mark E Sherman
Journal:  J Clin Endocrinol Metab       Date:  2012-06-22       Impact factor: 5.958

6.  Reliability of serum iron, ferritin, nitrite, and association with risk of renal cancer in women.

Authors:  M Aktar Ali; Arslan Akhmedkhanov; Anne Zeleniuch-Jaquotte; Paolo Toniolo; Krystyna Frenkel; Xi Huang
Journal:  Cancer Detect Prev       Date:  2003

7.  Physical activity and risk of endometrial adenocarcinoma in the Nurses' Health Study.

Authors:  Mengmeng Du; Peter Kraft; A Heather Eliassen; Edward Giovannucci; Susan E Hankinson; Immaculata De Vivo
Journal:  Int J Cancer       Date:  2013-11-29       Impact factor: 7.396

8.  Serum Estrogens and Estrogen Metabolites and Endometrial Cancer Risk among Postmenopausal Women.

Authors:  Louise A Brinton; Britton Trabert; Garnet L Anderson; Roni T Falk; Ashley S Felix; Barbara J Fuhrman; Margery L Gass; Lewis H Kuller; Ruth M Pfeiffer; Thomas E Rohan; Howard D Strickler; Xia Xu; Nicolas Wentzensen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2016-04-12       Impact factor: 4.254

9.  Circulating estrogens and postmenopausal ovarian and endometrial cancer risk among current hormone users in the Women's Health Initiative Observational Study.

Authors:  Britton Trabert; Sally B Coburn; Roni T Falk; JoAnn E Manson; Louise A Brinton; Margery L Gass; Lewis H Kuller; Thomas E Rohan; Ruth M Pfeiffer; Lihong Qi; Marcia L Stefanick; Nicolas Wentzensen; Garnet L Anderson; Xia Xu
Journal:  Cancer Causes Control       Date:  2019-09-21       Impact factor: 2.506

Review 10.  Obesity as an immune-modifying factor in cancer immunotherapy.

Authors:  Robert J Canter; Catherine T Le; Johanna M T Beerthuijzen; William J Murphy
Journal:  J Leukoc Biol       Date:  2018-05-15       Impact factor: 4.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.